Gout drug Colchicine to be tested as COVID-19 treatment in UK trial, Reuters
The RECOVERY trial, which is world's largest clinical trial of treatments for patients hospitalised with COVID-19, will randomly allocate at least 2,500 patients recruited to receive the anti-inflammatory colchicine, as inflammation is considered to play a major role in COVID-19.
Probenecid, a drug used to treat gout, has shown anti-viral capabilities, a study from the University of Georgia finds. It is among a variety of drugs being tested to treat COVID-19.
THE UNPRECEDENTED scale of the vaccine rollout has proven an effective shield against infection. For those who do become infected and become seriously ill, however, current go-to treatments are massively limited. One new study has suggested the gout drug remdesivir could be a prime candidate to treat severely ill COVID-19 patients.
This article summarizes the top 20 research studies of 2020 identified as POEMs (patient-oriented evidence that matters), including the two most highly rated guidelines of the year on gout and chronic obstructive pulmonary disease (COPD). Regarding COVID-19, handwashing and social distancing through stay-at-home orders or quarantine measures are effective at slowing the spread of illness. Use of proper face masks (not gaiters or bandanas) is also effective at preventing trans- mission. This is important because the virus can infect others during the presymptomatic phase. Aspirin can no longer be recommended for the primary...
AbstractCurrent data demonstrated that severe cases of coronavirus-disease-19 (COVID-19) require treatment with antiviral therapy, dexamethasone, supportive care, as well as some anti-rheumatic drugs, among them, cytokine inhibitors and colchicine. Colchicine is an anti-inflammatory drug that is being used in rheumatology for many years to treat mostly gout, calcium pyrophosphate deposition disease, and Familial Mediterranean Fever. Here, we present for the first time, two patients suffering from gout being treated with colchicine, who were affected from severe acute respiratory coronavirus-2 (SARS-CoV-2) syndrome. Both pa...
This article provides an overview of the mechanisms of action, benefits and side effects as well as the various possible uses of colchicine in rheumatology. Furthermore, a brief preview of potential new areas for use of the drug, which are also of interest to rheumatologists, are presented.PMID:34097101 | DOI:10.1007/s00393-021-01017-z
chvoerer Guillemin The World Health Organisation recommends monitoring the circulation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We investigated anti–SARS-CoV-2 total immunoglobulin (IgT) antibody seroprevalence and in vitro sero-neutralization in Nancy, France, in spring 2020. Individuals were randomly sampled from electoral lists and invited with household members over 5 years old to be tested for anti–SARS-CoV-2 (IgT, i.e., IgA/IgG/IgM) antibodies by ELISA (Bio-rad); the sero-neutralization activity was evaluated on Vero CCL-81 cells. Among 2006 individuals, the raw seroprevalen...
Conclusion We report a case of constrictive pericarditis with COVID-19, although this remained a differential among the co-existed immunoglobulin and autoimmune syndrome. Appropriate imaging, biomarkers and histology investigations need to be considered for rapid evaluation and escalation of treatment. Card iac manifestations are an important feature of COVID- 19. Further research is required to guide the management plans for similar cases.Disclosure Z. Alkutobi: None.G. Ansari: None.A. Nandagudi: None.
Early identification of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection enables rapid isolation to prevent transmission (European Centre for Disease Prevention and Control, National Institutes of Health, 2020, The World Health Organization). Symptoms of coronavirus disease 2019 (COVID-19) are common to a range of respiratory pathogens; therefore, accurate diagnostics are required for differential diagnosis.
CONCLUSION: The data collected does not support the concern for an increased risk of developing adverse reactions following soft tissue filler injections associated with the COVID-19 vaccines compared to that risk associated with other previously described triggers or the default risk following soft tissue filler injections. J Drugs Dermatol. 20(4):374-378. doi:10.36849/JDD.2021.6041.PMID:33852237 | DOI:10.36849/JDD.2021.6041